Table 3. Survival Outcomes Among Patients Receiving Apalutamide Plus ADT vs ADT Alone, Stratified by Receipt of Prior RP and Prior RT.
| Outcome | ADT alone, No. of events/patientsa | ADT plus apalutamide, No. of events/patients | Adjusted HR (95% CI) | P value for interaction |
|---|---|---|---|---|
| Metastasis-free survival | ||||
| Prior RP | ||||
| With | 87/127 | 78/269 | 0.18 (0.13-0.24) | .005 |
| Without | 150/263 | 154/520 | 0.29 (0.23-0.37) | |
| Prior RT | ||||
| With | 152/230 | 142/452 | 0.22 (0.17-0.28) | .09 |
| Without | 85/160 | 90/337 | 0.30 (0.22-0.40) | |
| Overall survival | ||||
| Prior RP | ||||
| With | 47/127 | 72/269 | 0.61 (0.42-0.89) | .11 |
| Without | 103/263 | 198/520 | 0.87 (0.69-1.11) | |
| Prior RT | ||||
| With | 91/230 | 154/452 | 0.77 (0.59-0.99) | .66 |
| Without | 59/160 | 116/337 | 0.84 (0.61-1.15) | |
Abbreviations: ADT, androgen deprivation therapy; HR, hazard ratio; RP, radical prostatectomy; RT, radiation therapy.
a
Placebo plus ADT.